Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 2
2005 5
2006 4
2007 4
2008 2
2010 6
2011 6
2012 2
2013 5
2014 4
2015 2
2016 3
2017 3
2018 3
2019 2
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B, Golding BT, Hardcastle IR. Zhang B, et al. Among authors: hardcastle ir. Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13. Future Med Chem. 2015. PMID: 25921402 Review.
Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB, Adiyasa I, Cano C, Hardcastle IR. Heptinstall AB, et al. Among authors: hardcastle ir. Future Med Chem. 2018 Jun 1;10(11):1369-1388. doi: 10.4155/fmc-2017-0246. Epub 2018 May 30. Future Med Chem. 2018. PMID: 29846081 Review.
Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR, Golding BT, Griffin RJ. Hardcastle IR, et al. Annu Rev Pharmacol Toxicol. 2002;42:325-48. doi: 10.1146/annurev.pharmtox.42.090601.125940. Annu Rev Pharmacol Toxicol. 2002. PMID: 11807175 Review.
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscombe E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, Carbain B, Castro J, Cons B, Cully SJ, Endicott JA, Fazal L, Golding BT, Griffin RJ, Haggerty K, Harnor SJ, Hearn K, Hobson S, Holvey RS, Howard S, Jennings CE, Johnson CN, Lunec J, Miller DC, Newell DR, Noble MEM, Reeks J, Revill CH, Riedinger C, St Denis JD, Tamanini E, Thomas H, Thompson NT, Vinković M, Wedge SR, Williams PA, Wilsher NE, Zhang B, Zhao Y. Chessari G, et al. Among authors: hardcastle ir. J Med Chem. 2021 Apr 8;64(7):4071-4088. doi: 10.1021/acs.jmedchem.0c02188. Epub 2021 Mar 24. J Med Chem. 2021. PMID: 33761253
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.
Matheson CJ, Coxon CR, Bayliss R, Boxall K, Carbain B, Fry AM, Hardcastle IR, Harnor SJ, Mas-Droux C, Newell DR, Richards MW, Sivaprakasam M, Turner D, Griffin RJ, Golding BT, Cano C. Matheson CJ, et al. Among authors: hardcastle ir. RSC Med Chem. 2020 May 22;11(6):707-731. doi: 10.1039/d0md00074d. eCollection 2020 Jun 1. RSC Med Chem. 2020. PMID: 33479670 Free PMC article.
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.
Al-Khawaldeh I, Al Yasiri MJ, Aldred GG, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Martin MP, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Thomas HD, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. Al-Khawaldeh I, et al. Among authors: hardcastle ir. J Med Chem. 2021 Jul 22;64(14):10001-10018. doi: 10.1021/acs.jmedchem.0c01249. Epub 2021 Jul 2. J Med Chem. 2021. PMID: 34212719
Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular Interactions.
Davison G, Martin MP, Turberville S, Dormen S, Heath R, Heptinstall AB, Lawson M, Miller DC, Ng YM, Sanderson JN, Hope I, Wood DJ, Cano C, Endicott JA, Hardcastle IR, Noble MEM, Waring MJ. Davison G, et al. Among authors: hardcastle ir. J Med Chem. 2022 Nov 24;65(22):15416-15432. doi: 10.1021/acs.jmedchem.2c01357. Epub 2022 Nov 11. J Med Chem. 2022. PMID: 36367089 Free PMC article.
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
Watson AF, Liu J, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu X, McDonnell JM, Newell DR, Noble ME, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR. Watson AF, et al. Among authors: hardcastle ir. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5916-9. doi: 10.1016/j.bmcl.2011.07.084. Epub 2011 Aug 9. Bioorg Med Chem Lett. 2011. PMID: 21875801
Structure-guided design of purine-based probes for selective Nek2 inhibition.
Coxon CR, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Coxon CR, et al. Among authors: hardcastle ir. Oncotarget. 2017 Mar 21;8(12):19089-19124. doi: 10.18632/oncotarget.13249. Oncotarget. 2017. PMID: 27833088 Free PMC article.
57 results